Promore Pharma AB

Promore Pharma AB

Promore Pharma AB

Date Founded



Fogdevreten 2,Solna, Stockholm 171 65

Type of Company


Employees (Worldwide)




Company Description

Promore Pharma AB is a biopharmaceutical company, which engages in the development of therapeutic peptides for the bioactive wound care market. Its projects include PXL01 and LL-37. The PXL01 project will be used for prevention of post-surgical adhesions and scars is being prepared for clinical Phase III-studies in patients undergoing tendon repair surgery in the hand. The LL-37 project will used to prepare for a clinical Phase IIb study in patients with venous leg ulcers. The company was founded by Mona Ståhle and Johan Heilborn on January 29, 2003 and is headquartered in Solna, Sweden.

Contact Data
Trying to get in touch with decision makers at Promore Pharma AB? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer

Chief Operating Officer

Chief Scientific Officer

Office Manager

Assistant Office Manager

Board of Directors

Vice Chairman at Mobidiag Oy

Chairman at MDA Management AB

Industrial Advisor at Segulah Advisor AB

Partner at Rosetta Capital Ltd.

Managing Director at Midroc New Technology AB

Former Vice President-Research & Development at Pharma Research Products Co., Ltd.

Paths to Promore Pharma AB
Potential Connections via
Relationship Science
Promore Pharma AB
Recent Transactions
Details Hidden

Pharma Research Products Co., Ltd. purchases Promore Pharma AB from Pergamum AB

Details Hidden

Promore Pharma AB issued SEK Units Consisting of Common Stock and Warrants

Details Hidden

Midroc New Technology AB, Pergamum AB, Karolinska Development AB purchase Promore Pharma AB

Transaction Advisors

Advised onPromore Pharma AB issued SEK Units Consisting of Common Stock and Warrants

Investment Advisor

Advised onPromore Pharma AB issued SEK Units Consisting of Common Stock and Warrants

Advisors & Consultants

Chief Financial Officer at Cinclus Pharma Holding AB

Key Stats and Financials As of 2019
Market Capitalization
Total Enterprise Value
Earnings Per Share
Enterprise Value / Sales
TEVNet Income
Debt TEV
Three Year Compounded Annual Growth Rate Of Revenue
Net Profit
Total Debt
Total Equity
Details Hidden

Co-Founder at Promore Pharma AB

Details Hidden

Senior Physician & Professor, Department of Medicine at Karolinska Institutet

Details Hidden

KD's investment approach aims to transfer life sciences innovations into commercial applications while improving human health. They are an early investor with the objective of being the lead investor. They generally maintain a significant position in their portfolio firms until exit. They endeavor to rapidly build value in high risk opportunities.Among key investment criteria, they seek innovations, either pharmaceutical or medical technology applications, which address unmet medical needs. KD looks for opportunities displaying a strong IP position, preferably with a patent application, as well as unique skills or processes.KD works closely with regional Nordic academic and research institutions. Their deal flow agreement with Karolinska Institutet Innovations ensures priority access of promising opportunities at a very early stage. In addition to capital infusion, the firm supports their investments through business development expertise, technical specialists and access to their wide-ranging professional network.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Promore Pharma AB. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Promore Pharma AB's profile does not indicate a business or promotional relationship of any kind between RelSci and Promore Pharma AB.